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Abstract 
 
Biobanks are increasingly being linked together into global networks in order to maximise 
their capacity to identify causes of and treatments for disease. While there is great 
optimism about the potential of these biobank networks to contribute to personalised and 
data-driven medicine, there are also ethical concerns about, among other things, risks to 
personal privacy and exploitation of vulnerable populations. Concepts drawn from theories 
of globalisation can assist with the characterisation of the ethical implications of biobank 
networking across borders, which can, in turn, inform more ethically sophisticated 
responses. Using the China Kadoorie Biobank as a case study, we show how distinguishing 
between the subnational, transnational, supranational and extranational spheres of 
operation and influence can help researchers, institutions and regulators to understand and 
manage the ethical issues raised by the globalisation of biobanking.  
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Globalisation and the ethics of transnational biobank networks 
Introduction 
Biobanks, which can be defined as “structured collections of biological samples and 
associated data, stored for the purposes of present and future research”(Parodi 2015), are 
becoming increasingly important in scientific and medical research, and are believed to be 
an important foundation of genomic and personalised medicine. Advances in computational 
and information technology and data linkage platforms have greatly enhanced the potential 
of biobanks to identify biomarkers and develop new treatments.  
Typically, biobanks have been housed within, or associated with, academic medical research 
institutions, governments, or commercial organisations (such as biotechnology or 
pharmaceutical companies). Increasingly, however, single institution biobanks are becoming 
unsustainable, both because they lack sufficient informational depth and also because they 
are operationally isolated. Biobanks are therefore frequently becoming part of national or 
international networks. This facilitates high powered molecular epidemiology—enabling 
researchers to make fine comparisons, to accommodate population heterogeneity, identify 
rare events, and develop predictive analytics (or “risk scores”) for treating individuals. In this 
way, biobank networking is closely intertwined with the promise of big data, and offers 
opportunities for collaboration and efficiencies of scale. 
While globalisation affords biobanks enormous possibilities, the global networking of 
biobanks is associated with significant socio-cultural, ethical and regulatory challenges. 
These include challenges that arise in the context of local biobanking (including consent, 
privacy, return of research results, custodianship, commodification and exploitation), but 
which become increasingly complex as biobanks network, and also new issues created by 
the networking of biobanks. In this paper we outline some of the ways that biobanks can 
globalise, and elucidate some relevant concepts from theories of globalisation.  Then, using 
the China Kadoorie Biobank as a case study, we show how concepts drawn from theories of 
globalisation can help to inform ethical approaches to issues that arise when biobanks 
network across international borders. 
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Modes of Biobank Globalisation  
There is nothing new about biobanking (Hoeyer 2008). People have stored human biological 
materials and used them in research for decades. However in the 1990s, increasing 
attention turned to the ethical, social and legal consequences of biobanking. This was 
fomented by a number of forces such as the patient rights’ movement, increasing 
commercialisation of medical research, and developments in genetics and data science. 
Moral attention was also drawn to the tension between the commodification and 
depersonalisation of human tissue on the one hand, and its residual biological 
personification and cultural identification on the other hand. The increasing capacity, reach 
and accessibility of genomic medicine has made it even more apparent that tissue retains its 
personal and cultural identity even when it becomes disembodied. The persisting personal 
and cultural identity that attaches to human tissue even when it is disembodied is 
increasingly recognised in the context of genomics. While relevant to individual biobanks, 
these issues become even more salient and challenging as biobanks globalise. 
Biobanks can globalise in three principal ways. The first and most obvious way in is when a 
single biobank operates across international borders. An example of this is the for-profit 
incorporated company 23andMe which offers direct-to-consumer DNA analysis and retains 
saliva samples and/or genetic data from its customers. While the organisation’s operations 
have been restricted in some jurisdictions,1 it can accept saliva samples from anywhere in 
the world and retain the right to access and analyse customers’ samples and data for future 
research. 
A second way in which biobanks can globalise is that they can pool and/or centralise their 
resources across international boundaries. They can, for example, share facilities (e.g.  
“storage networks”), pool or centralise information technology platforms (e.g. “catalogue 
networks”), and/or form partnership networks to centralise and coordinate administration, 
including staffing, recruitment and other organisational functions. 
The third way that biobanks can globalise is by distributing and compartmentalising their 
operations. In these situations, different elements of the biobank’s operations – including 
                                                      
1 For example, until 2016, 23andMe was only permitted to provide ancestry information to US customers, and 
other countries have varying restrictions on the information that can be provided to customers. 
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financing, participant recruitment, sample collection, sample storage, data storage, analysis, 
governance oversight, etc. – are undertaken in different countries. Generally, operational 
components will be located in those countries with the most favourable ethical, regulatory 
and legal conditions, or where the relevant kind of expertise is located. 
 
 Conceptualisations of Globalisation 
A number of scholars have developed theoretical frameworks and elucidated concepts for 
understanding social activities that occur both locally and across national borders. Key 
theories and concepts include Habermas’s theory of postnational constellations (Habermas 
2001), Appadurai’s notion of global cultural flows (Appadurai 2010), and Harvey’s concept 
of time-space compression (Harvey 1990). The concept of postnationalism, which is 
elaborated in all of these approaches, describes the reduction in the importance of the 
nation state and national identity in the face of internationalisation, the increasing plurality 
of actors involved in governance, both within and across nation states, and the challenges 
and opportunities to national structures afforded by subnational, transnational, and 
supranational formations.  
At the subnational level – from the perspective of a single country – the increasing and 
intensifying movement of people across borders has led to more widespread diasporic 
communities and more multicultural societies. At the transnational level – that is, spanning 
across national borders – technologies of communication, travel and exchange have 
afforded new alliances. At the supranational level, globalisation has created organisations 
such as the World Health Organisation and the World Bank, whose operations and 
jurisdictions “sit above” national governance structures. Together, these formations 
displace, challenge and erode the authority, legitimacy and integrative capacities of the 
nation-state at multiple levels, thus creating and supporting postnational ideas and 
structures in which activities escape the jurisdiction of any particular nation and exist, either 
theoretically or tangibly, in extranational territory. This exemplifies the concept of 
postnationalism, the view that national citizenship is becoming decreasingly relevant as 
governments extend rights to people who are not their citizens. In this postnational context, 
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international  organisations, such as the World Health Organisation, have become 
increasingly important in safeguarding human rights across borders (Jacobsen 1996).  
Global biobank networks can be conceptualised as existing in this “extranational” space 
because they selectively and differentially share, transfer, transport and store material and 
data across national boundaries. This disrupts existing arrangements between peoples, 
institutions, and nations and remakes social, political, organisational, economic and 
regulatory relations along the way, subsuming local practices under the standards, 
structures and norms of international biomedical science. Concepts of globalisation can help 
to inform normative considerations and practical responses to the globalisation of biobanks 
because  of the ways in which human biological samples are extracted multinationally; 
contributors and beneficiaries are distributed transnationally; and biobanks can be 
governed, and influence scientific practice, supranationally, 
 
The China Kadoorie Biobank 
The China Kadoorie Biobank (CKB) provides a model for examining the processes and 
implications of the globalisation of biobanks. The CKB was established to enable research 
into the genetic and environmental factors associated with common chronic diseases in 
China. Although initial funding for the project came from a Hong Kong-based charitable 
trust, from the start it was a collaborative project between the University of Oxford and 
Chinese researchers. This collaboration was partly motivated by researchers from Oxford’s 
Clinical Trials Service Unit experiencing difficult negotiations with the UK Biobank and 
seeking another large-scale biobank project to support prospective research into chronic 
disease prevention and treatment. It also followed on from decades of productive 
collaboration and trust between Oxford researchers and the Chinese Centre for Disease 
Control (Chen 2013). More than half a million participants from 10 geographical areas in 
China were recruited into the prospective cohort study between 2004 and 2008. All 
participants provided extensive data in addition to blood samples, with follow-up 
information gathered from 5% of participants (selected randomly) every four to five years 
(China Kadoorie Biobank 2017d). Sample and data collection for the CKB was undertaken by 
teams of qualified health researchers and relied heavily on the involvement of local health 
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and administrative (government) authorities in the selected communities (Chen 2013). All 
samples and associated data are stored in a central repository in Beijing, with cryopreserved 
plasma aliquots from each participant also sent to Oxford for further analysis and storage.  
Although focused on the Chinese population, the study is being conducted and the biobank 
administered jointly by the University of Oxford’s Clinical Trial Service Unit & 
Epidemiological Studies Unit, and the Chinese Academy of Medical Sciences. Funding for the 
biobank has been provided by a range of Chinese and UK funders. Initial financial support 
was provided by the Hong Kong government, with ongoing operations being supported by 
funders across the world including the Wellcome Trust, UK Medical Research Council, British 
Heart Foundation, Cancer Research UK, the Chinese Natural Science Foundation, and the 
Chinese Ministry of Science and Technology.  
Collaborating institutions include universities and research centres in Australia, Sweden, 
France, Finland and China. Researchers from around the world can apply to gain access to 
the data in the CKB, although access to biological samples is strictly controlled due to the 
small volume of biomaterials collected from each participant in the study. Researchers can 
also apply for access to baseline data, follow-up prospective data and from 2018 they will be 
able to access genotype datasets. The CKB’s Data Access and Sample Sharing Policy (China 
Kadoorie Biobank 2017c) requires researchers to demonstrate that they are employees of a 
recognised institution that has policies and procedures in place to ensure the appropriate 
and responsible use of the dataset. The CKB policy aligns with the Data Access and Sharing 
Policy of the Nuffield Department of Population Health. An Independent Access Committee 
oversees data access for the CKB, providing guidance and reviewing applications that raise 
specific issues. 
 
Ethical Responses to Global Biobank Networking 
When biobanks network their operations across international borders, the ethical issues of 
local relevance to specific biobanks become increasingly complex. Here we will focus on the 
following issues: consent, participant privacy and confidentiality, benefit sharing and trust. 
These particular issues have been chosen both because of their centrality to biobanking 
ethics generally, but also because they become more complex when biobanks network 
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globally. We will give a brief overview of each of these issues, explain how they become 
more complex in the context of global networking, and then use the example of the China 
Kadoorie Biobank to show how a postnational understanding of globalisation can practically 
enhance ethical responses to these issues. 
 
Consent 
Consent is an important issue in biobanking, because the kind of consent that a donor gives 
will determine how their tissue sample and its associated data can be used. Donors might 
consent only to a single, specific use of their sample. Project-specific consent, however, 
significantly limits the utility of a sample for research purposes. For this reason, broad rather 
than specific informed consent is usually sought as this provides for long-term storage and 
unspecified or unknown future research use. Alternative models of consent provide for both 
broad and specific consent.  Dynamic consent, for example, uses technology platforms to 
engage donors in an ongoing way, in decisions about what kind of research they wish their 
information to be used for.  
When a biobank shares samples or data in an international networking arrangement, the 
connection between the original donor and the researchers using their sample becomes 
increasingly distant. This disconnection can have implications for the control that a donor 
can exercise over their sample, and the extent to which the networked biobank partners are 
required to uphold the original biobank’s obligation to donors. As global biobank networks 
operate on a transnational scale, they may not be bound by the (subnational) laws of a 
single jurisdiction’s legislative and regulatory requirements with respect to their obligations 
to donors. Consent requirements can vary substantially between countries. Furthermore, 
different countries can take different approaches to how stringently they enforce their 
regulations relating to consent. Similarly, if global biobank networks operate in an 
extranational space, then there is a risk that donors’ rights in relation to the consent that 
they granted when giving their sample could be overturned or no longer relevant in another 
jurisdiction. Therefore it is essential that when biobanks globalise, clear arrangements are 
made for how consent obligations to donors will be upheld. 
In the context of the China Kadoorie Biobank, regulatory challenges related to consent were 
addressed by ensuring that the project adhered to the more stringent standards of 
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regulation that governed the UK partners in the project. In a 2013 multi-method empirical 
study, Scott (Scott et al. 2012) noted how the study’s central coordinating centres placed 
significant emphasis on the importance of obtaining informed consent, and that regional 
staff in various operational branches were urged to follow prescribed processes for 
obtaining broad consent.  
However, interviews and focus group feedback identified some misunderstandings among 
donors. Participation in the CKB was often understood to be a means of accessing free 
health examinations. Indeed, the benefit of free physical examinations was one of the two 
main reasons reported as motivating people to participate in the study, with the other being 
the public good of advancing scientific and medical research. These misunderstandings 
potentially undermine the legitimacy of consent to participation in the CKB, and the use of 
samples of data both locally and internationally. 
Issues surrounding consent in the context of the globalisation of biobanks are made more 
complex by differences in values across different cultures.  For example, an analysis of 
consent forms in East Asia found that they performed a broader social and communicative 
function than comparable documents from genomic research projects in Europe, the UK and 
Africa (Yoshizawa et al. 2017). This reflects earlier findings that in East Asian countries, 
informed consent is more of a collective process than an individual one (Yoshizawa et al. 
2014), with significant involvement of participants’ family and community members in the 
decision making process. Collective consent processes were involved in the CKB case, as 
local community members—both administrative and medical—played a significant role in 
recruiting participants for the study. This locally distributed decision-making then 
underwent a shift as CKB moved out of the subnational context—with its emphasis on 
family and community—and adopted UK standards for participant consent, which is a more 
individualistic approach to informed consent. The decision by the CKB to adhere to 
transnational (UK and European) standards in relation to consent demonstrates a 
commitment to seek and implement more stringent standards for the benefit of 
participants. However, this approach contrasts with the recruitment methods for the study, 
which depended on the active involvement of local community networks. 
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Privacy and confidentiality 
When an individual donates a sample to a biobank and allows it to be used in health and 
medical research, there are both moral standards and regulatory requirements with respect 
to the individual’s privacy and confidentiality. These generally aim to enable research (a 
public good) while also respecting an individual donor’s right to privacy and protecting them 
from harm arising from use of their data (Dove et al. 2014). While at one time donors could 
be given assurances that their data would remain private and secure, advances in genomic 
technologies and big data, and the imperative to make data accessible, means that  an 
individual’s privacy can no longer be guaranteed (Lunshof et al. 2008).  
When biobanks enter into networking arrangements, particularly across international 
borders, it becomes exponentially more difficult to maintain donors’ privacy and 
confidentiality. (Chadwick and O’Connor 2016). Furthermore, as with consent, when a 
donor’s tissue or data are shared with institutions in other jurisdictions, that institution 
might be bound by different legal and regulatory frameworks to those that applied in the 
jurisdiction in which the donor gave their tissue. This means that donors might not be 
protected by their own country’s privacy legislation when their sample or data is used in 
another jurisdiction. 
When the CKB began, it did not share its data as baseline measurements were collected and 
aggregated. However, since 2016 researchers from around the world in any reputable 
research organisation (including commercial organisations) have been able to apply to have 
access to the samples and data held in the CKB. Available datasets include the baseline 
survey data, follow-up and resurvey data, as well as blood-based SNP (single nucleotide 
polymorphism) genotyping datasets (China Kadoorie Biobank 2017b). In the case of the CKB, 
this kind of transnationality has led to the adoption of higher standards of privacy 
protection than would usually exist in China, which lacks robust national mechanisms for 
governing biomedical research (Chen 2013). This arrangement not only offers research 
participants greater technological and regulatory protection but also creates data 
management resources that are beneficial to Chinese and overseas researchers. However, 
transnationality does not necessarily always work to protect research participants as 
collaborating countries might also have less rigorous and more lenient ethical and 
regulatory standards and so work to undermine participant protection. Indeed, some would 
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argue that genetic researchers can no longer guarantee the privacy of participants (Lunshof 
et al 2008). This could be exacerbated if a biobank network actively engages in regulatory 
arbitrage and seeks to locate its data storage functions in the jurisdictions with less onerous 
privacy regulations. Another consideration is that the imposition of UK standards for 
safeguarding patient data leads to a more individualistic emphasis on participant rights. This 
does not necessarily align with the tendency of East Asian countries to emphasise the 
broader societal benefits of participating in genomic research (Yoshizawa et al. 2017). 
 
Benefit sharing 
A significant ethical consideration, particularly when different countries become involved in 
a biobanking research project, is how to ensure the equitable distribution of the benefits of 
research. While individual countries have different subnational regulations about the 
obligations of researchers to research participants, when samples are collected in one 
country and sent to another for analysis, the research project is operating in a transnational 
context and hence these obligations become less clear. Chadwick and O’Connor (Chadwick 
and O’Connor 2016) point out that benefit sharing between countries involved in 
biobanking research is especially pertinent when there are economic disparities between 
the countries involved. The primary concern they identify is that comparatively 
disadvantaged communities will donate samples for medical research – bearing the burden 
of risks that research participation entails – and the benefits resulting from the research – 
either monetary or in terms of healthcare advances – tend to accrue to the wealthier, more 
advantaged countries whose medical research institutes obtain the samples and conduct 
the research. As early as 2000, the Human Genome Organization (HUGO) clarified that 
benefit sharing goes beyond obligations not to harm research participants (Knoppers et al. 
2000). HUGO encouraged researchers to consider how benefits of research such as direct 
healthcare, provision of technologies, and contributions to broader community 
infrastructure can be distributed to communities that contribute to medical research. They 
also recommended that any profit-making entities engaged in medical research donate a 
percentage of profits to improving healthcare infrastructure or supporting humanitarian 
efforts in communities that have contributed to their research. 
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The CKB currently releases datasets to CKB researchers first, then allows limited access for 
other researchers in China only for a period of three to six months. Researchers who access 
CKB data are required to publish their findings and return them to CKB, both for the benefit 
of future research and for the public good (China Kadoorie Biobank 2017a). Beyond that, 
publicly available CKB documentation does not indicate any further requirements for 
benefit sharing with donors to the study from researchers who use the samples or data. 
Empirical examination of the motivations of donors to the CKB (Chen 2013) found that they 
participated in the hope that they would obtain some benefit, either for themselves or their 
communities. As described above, a key reason for participating in the CKB was that donors 
wanted to access the physical examinations that were conducted as part of the project. 
They were also motivated by an interest in contributing to scientific research, which reflects 
a general trend observed in East Asian countries, where researchers have been observed to 
have a tendency to emphasise the virtue of participating in medical research for the 
purpose of advancing medical and scientific knowledge (Yoshizawa et al. 2017). The ethical 
issue here is how the transnational activities of biobanks such as the CKB flow to the  
subnational realm. For instance, what tangible benefits drawn from the research findings (or 
profits derived from them) could be distributed to the donor communities, such as health 
infrastructure, improved medical care, and so on? It is therefore crucial that, as banks like 
the CKB enable research in many countries, donor communities remain connected with the 
benefits of the research that their samples make possible. 
 
Trust 
Trust is a central issue that underpins many of the ethical and regulatory challenges in 
biobanking, not least because without trust people are unlikely to volunteer their biological 
samples and data for research use. In order to agree to relinquish control of one’s tissue 
sample and its associated data, a typical person would require some degree of trust that the 
institution conducting the research will not misuse their sample or information in a way that 
could harm them (or others). The trust on which such arrangements are usually entered into 
are often based on the donor’s perception of the institution or individuals involved with the 
research as trustworthy, either by virtue of their institutional reputation or by some other 
kind of interpersonal trust grounded in a relationship with the individual/s.  
  12 
This trust is often transitive: when a person trusts their doctor and the hospital they attend, 
then by virtue of that trust they also trust the laboratory technician and the researcher 
analysing their sample, and so on, even though they do not have a direct relationship with 
the latter professionals or specific knowledge of their credentials. It is likely that the 
transitivity of trust is placed under tension when it stretches across international borders. If 
a person in a rural village in China agrees to participate in a research study on the urging of 
their local community doctor, they would likely do so on the basis of the trustworthiness 
that they attribute to the doctor. While the donor likely understands that the doctor will not 
retain personal control over their sample and data, she probably does not realise that teams 
of researchers in Oxford – and indeed, years later, researchers in other countries who have 
paid for access to the CKB samples – can use her tissue and associated data for research 
purposes. 
In the case of the CKB, community members’ trust in their local authorities and doctors was 
a significant factor in the establishment of the biobank and the recruitment of participants. 
Village administration bodies and street communities, for example, played a crucial role in 
promoting involvement with the project (Chen 2013). Trusted local community members 
such as doctors from community health centres went door-knocking among their 
constituents, encouraging them to donate to the biobank. The trustworthiness of local 
doctors was also – significantly – transitive, in the sense that community members’ trust in 
local doctors led them to agree to participate in a study run by central coordinating 
authorities in both Beijing and Oxford. 
 Trust is subject to the dynamics of globalisation. The initial relationship that encouraged 
participation in the CKB – that is the perceived trustworthiness of local doctors and 
authorities – is geographically local (i.e. is subnational). However participants need to 
understand and accept that they are participating in a transnational project with 
supranational arrangements. Sutrop explores the nature of trust required by participants in 
human genetic databases, distinguishing between trust in individuals and in institutions 
(Sutrop 2007). The trust that individual participants have in their local doctors and 
authorities is, to some extent, transferable in that it extends from trust in individuals to 
trust in organisations with which those individuals are associated. However this 
interpersonal dimension of trust also means that as participants become further removed 
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from the researchers working with their data, the trust relationship could weaken. In this 
way, the globalisation of biobanks could have the effect of diluting participants’ trust in 
researchers as biobanks aggregate transnationally. 
The application of local (subnational) governance standards described above, therefore, 
impacts not only on consent and privacy protection but also on trust. O’Neill (O'Neill 2002) 
explains that “trustworthiness is expressed through institutions, practices and actions”. This 
means that partnering with trustworthy institutions from other jurisdictions can be a way of 
improving trust. While individual donors might not be concerned with the data access 
policies that the CKB has adapted from various UK and European institutions, their local 
doctors or others higher up the “trust chain” might feel more justified in promoting the 
initiative locally if they have confidence in the governing institutions of the wider project. 
Conversely, trust might be threatened if the CKB partners with institutions in countries with 
less rigorous governance arrangements. 
 
Conclusion 
We have argued that concepts drawn from theories of globalisation theories can help us to 
understand and make sense of the ethical issues that arise when biobanks globalise. The 
China Kadoorie Biobank provides a good illustration of the issues that are at stake, because 
it is an example of a biobanking project that has shifted from a subnational to a 
transnational context, with supranational oversight. An awareness of these dynamics will 
support the development of ethically robust postnational responses to globalisation of 
biobank networks. 
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